Radiant Biotherapeutics

We're excited to emerge from #stealth mode today with a $8M #seed #financing. Radiant Biotherapeutics is a revolutionary antibody platform company developing multi-valent, multi-specific therapeutics. Based on foundational IP from the labs of Dr. Jean-Philippe Julien at The Hospital for Sick Children (SickKids) and Dr. Bebhinn Treanor at the University of Toronto, Radiant was created by Amplitude Ventures which also led the seed round along with launch partner, SickKids and additional investors Alexandria Investments, FACIT and TIAP - Toronto Innovation Acceleration Partners. https://lnkd.in/em2GgCxA  

Researchers from several teams are finding that antibodies from the blood of patients suffering from Long Covid can cause similar symptoms when injected into mice. The findings suggest that Long Covid is an immune-mediated disorder in which a patient’s antibodies attack their own tissues. Radiant Biotherapeutics is a leader in antibody science, and is developing the Multabody™ platform – a breakthrough biologic that is multi-valent and multi-specific. Read the full report by Yale Medicine here. And learn more about Radiant’s antibody science at www.radiantbio.com.

Radiant’s Multabody™ platform enables multi-valent, multi-specific antibodies that have the potential to transform the treatment of cancer, inflammation, infections and other heterogeneous diseases. This breakthrough in antibody engineering combines avidity – superior binding power – with multi-specificity to create multifunctional biologics with the potential to unlock biology not achievable with current antibodies. Multabodies are a new class of biologics built on a modular, fully human scaffold, simplifying development while leveraging existing antibody manufacturing processes. We are rapidly advancing this superior next- generation therapeutic platform for a variety of indications. Learn more at radiantbio.com #Multabody #RadiantBio #antibodies

#ICYMI: #TeamRadiant was honored to receive a $2M grant from the Bill & Melinda Gates Foundation to develop next-gen #HIV #biologics using our Multabody™ platform. These potential treatments may be able to destroy latent stores of HIV and eliminate circulating viral particles of the virus. Read more here. https://lnkd.in/dZJB9P-G

Our leadership team is thrilled to be at #JPM2024 for a busy week of learning, networking and educating the #biopharma community about the potential of our Multabody™ platform to develop multi-functional biologics to address a range of difficult-to-treat diseases. #TeamRadiant

It’s been an exciting year of growth for Radiant Biotherapeutics, as we emerged from stealth mode with an $8M seed round, two pharma partnerships and expanded #TeamRadiant with new colleagues. Additionally, the science behind our Multabody™ platform was presented at scientific conferences including the Antibody Engineering & Therapeutics meeting and published in Science Translational Medicine. We were also honored to be recognized by Labiotech.eu as one of Toronto's #biotech companies to watch!   Looking ahead to 2024, Radiant is well positioned to build upon this momentum as we advance our preclinical candidates to treat cancer, autoimmune and infectious diseases. We are kicking off the New Year at the J.P. Morgan 42nd Annual Healthcare Conference (#JPM2024). We look forward to sharing additional scientific and corporate milestones in the coming year. Wishing a happy, healthy New Year to all! 

After a productive year, #TeamRadiant gathered for a wonderful holiday party! We celebrated all of the hard work and achievements in 2023 and look forward to another great year ahead! #HappyHolidays to all!

Thank you to all who attended Radiant's Chief Scientific Officer Jo Hulme's presentation at this week's Antibody Engineering & Therapeutics conference regarding Multabodies™ and how #TeamRadiant is using this approach to develop next-generation therapeutics to improve the treatment of #cancer, #autoimmunediseases and #infectiousdiseases. #ANTIBODYENG

We're excited to announce that Radiant's Chief Scientific Officer, @Jo Hulme, will present "Multabodies: Exploiting Avidity and Multi-specificity to Achieve Ultra-potent Biologics" during the Antibody Engineering & Therapeutics conference this Thursday, December 14 at 3:30 p.m. PT in San Diego. She will discuss this promising approach that #TeamRadiant is using to develop next-generation therapeutics to tackle difficult-to-treat diseases such as #cancer, #autoimmunediseases and #infectiousdiseases. Click here to learn more about the conference. #ANTIBODYENG  https://lnkd.in/ebbbPag

We look forward to learning about the exciting innovation and research from our #biopharma colleagues being presented at the 65th American Society of Hematology Annual Meeting that starts tomorrow. Learn more about what is being presented. #ASH23  https://lnkd.in/eUZR9BmC